

United States Type I Hyperlipoproteinemia Drug Market Report 2018

<https://marketpublishers.com/r/U9AE14C1E4FEN.html>

Date: January 2018

Pages: 100

Price: US\$ 3,800.00 (Single User License)

ID: U9AE14C1E4FEN

Abstracts

In this report, the United States Type I Hyperlipoproteinemia Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Type I Hyperlipoproteinemia Drug in these regions, from 2013 to 2025 (forecast).

United States Type I Hyperlipoproteinemia Drug market competition by top manufacturers/players, with Type I Hyperlipoproteinemia Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

Aegerion Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Novartis AG

uniQure N.V.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Alipogene Tiparvovec

CAT-2003

ISIS-APOCIIIIRx

Lomitapide Mesylate

Pradigastat Sodium

Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospital

Clinic

Others

If you have any special requirements, please let us know and we will offer you the report

as you want.

Contents

United States Type I Hyperlipoproteinemia Drug Market Report 2018

1 TYPE I HYPERLIPOPROTEINEMIA DRUG OVERVIEW

1.1 Product Overview and Scope of Type I Hyperlipoproteinemia Drug

1.2 Classification of Type I Hyperlipoproteinemia Drug by Product Category

1.2.1 United States Type I Hyperlipoproteinemia Drug Market Size (Sales Volume) Comparison by Type (2013-2025)

1.2.2 United States Type I Hyperlipoproteinemia Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017

1.2.3 Alipogene Tiparvovec

1.2.4 CAT-2003

1.2.5 ISIS-APOCIII Rx

1.2.6 Lomitapide Mesylate

1.2.7 Pradigastat Sodium

1.2.8 Others

1.3 United States Type I Hyperlipoproteinemia Drug Market by Application/End Users

1.3.1 United States Type I Hyperlipoproteinemia Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 United States Type I Hyperlipoproteinemia Drug Market by Region

1.4.1 United States Type I Hyperlipoproteinemia Drug Market Size (Value) Comparison by Region (2013-2025)

1.4.2 The West Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.4.3 Southwest Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.4.4 The Middle Atlantic Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.4.5 New England Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.4.6 The South Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.4.7 The Midwest Type I Hyperlipoproteinemia Drug Status and Prospect (2013-2025)

1.5 United States Market Size (Value and Volume) of Type I Hyperlipoproteinemia Drug (2013-2025)

1.5.1 United States Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2013-2025)

1.5.2 United States Type I Hyperlipoproteinemia Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Type I Hyperlipoproteinemia Drug Sales and Market Share of Key Players/Suppliers (2013-2018)

2.2 United States Type I Hyperlipoproteinemia Drug Revenue and Share by Players/Suppliers (2013-2018)

2.3 United States Type I Hyperlipoproteinemia Drug Average Price by Players/Suppliers (2013-2018)

2.4 United States Type I Hyperlipoproteinemia Drug Market Competitive Situation and Trends

2.4.1 United States Type I Hyperlipoproteinemia Drug Market Concentration Rate

2.4.2 United States Type I Hyperlipoproteinemia Drug Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Type I Hyperlipoproteinemia Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Type I Hyperlipoproteinemia Drug Sales and Market Share by Region (2013-2018)

3.2 United States Type I Hyperlipoproteinemia Drug Revenue and Market Share by Region (2013-2018)

3.3 United States Type I Hyperlipoproteinemia Drug Price by Region (2013-2018)

4 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Type I Hyperlipoproteinemia Drug Sales and Market Share by Type (Product Category) (2013-2018)

4.2 United States Type I Hyperlipoproteinemia Drug Revenue and Market Share by Type (2013-2018)

4.3 United States Type I Hyperlipoproteinemia Drug Price by Type (2013-2018)

4.4 United States Type I Hyperlipoproteinemia Drug Sales Growth Rate by Type

(2013-2018)

5 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Type I Hyperlipoproteinemia Drug Sales and Market Share by Application (2013-2018)

5.2 United States Type I Hyperlipoproteinemia Drug Sales Growth Rate by Application (2013-2018)

5.3 Market Drivers and Opportunities

6 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Aegerion Pharmaceuticals, Inc.

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Type I Hyperlipoproteinemia Drug Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)

6.1.4 Main Business/Business Overview

6.2 Catabasis Pharmaceuticals, Inc.

6.2.2 Type I Hyperlipoproteinemia Drug Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)

6.2.4 Main Business/Business Overview

6.3 Isis Pharmaceuticals, Inc.

6.3.2 Type I Hyperlipoproteinemia Drug Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)

6.3.4 Main Business/Business Overview

6.4 Novartis AG

6.4.2 Type I Hyperlipoproteinemia Drug Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Novartis AG Type I Hyperlipoproteinemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)

6.4.4 Main Business/Business Overview

6.5 uniQure N.V.

6.5.2 Type I Hyperlipoproteinemia Drug Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 uniQure N.V. Type I Hyperlipoproteinemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)

6.5.4 Main Business/Business Overview

7 TYPE I HYPERLIPOPROTEINEMIA DRUG MANUFACTURING COST ANALYSIS

7.1 Type I Hyperlipoproteinemia Drug Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Type I Hyperlipoproteinemia Drug Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Type I Hyperlipoproteinemia Drug Major Manufacturers in 2017

8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
 - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
 - 10.1.1 Substitutes Threat
 - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

11 UNITED STATES TYPE I HYPERLIPOPROTEINEMIA DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

- 11.1 United States Type I Hyperlipoproteinemia Drug Sales Volume, Revenue Forecast (2018-2025)
- 11.2 United States Type I Hyperlipoproteinemia Drug Sales Volume Forecast by Type (2018-2025)
- 11.3 United States Type I Hyperlipoproteinemia Drug Sales Volume Forecast by Application (2018-2025)
- 11.4 United States Type I Hyperlipoproteinemia Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

- 13.1 Methodology/Research Approach
 - 13.1.1 Research Programs/Design
 - 13.1.2 Market Size Estimation
 - 13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Type I Hyperlipoproteinemia Drug

Figure United States Type I Hyperlipoproteinemia Drug Market Size (K Pcs) by Type (2013-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume Market Share by Type (Product Category) in 2017

Figure Alipogene Tiparvovec Product Picture

Figure CAT-2003 Product Picture

Figure ISIS-APOCIII Rx Product Picture

Figure Lomitapide Mesylate Product Picture

Figure Pradigastat Sodium Product Picture

Figure Others Product Picture

Figure United States Type I Hyperlipoproteinemia Drug Market Size (K Pcs) by Application (2013-2025)

Figure United States Sales Market Share of Type I Hyperlipoproteinemia Drug by Application in 2017

Figure Hospital Examples

Table Key Downstream Customer in Hospital

Figure Clinic Examples

Table Key Downstream Customer in Clinic

Figure Others Examples

Table Key Downstream Customer in Others

Figure United States Type I Hyperlipoproteinemia Drug Market Size (Million USD) by Region (2013-2025)

Figure The West Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure Southwest Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure The Middle Atlantic Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure New England Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure The South of US Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure The Midwest Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) and Growth Rate (2013-2025)

Figure United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate (2013-2025)

Figure United States Type I Hyperlipoproteinemia Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales Share by Players/Suppliers (2013-2018)

Figure 2017 United States Type I Hyperlipoproteinemia Drug Sales Share by Players/Suppliers

Figure 2017 United States Type I Hyperlipoproteinemia Drug Sales Share by Players/Suppliers

Figure United States Type I Hyperlipoproteinemia Drug Market Major Players Product Revenue (Million USD) (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) by Players/Suppliers (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Revenue Share by Players/Suppliers (2013-2018)

Figure 2017 United States Type I Hyperlipoproteinemia Drug Revenue Share by Players/Suppliers

Figure 2017 United States Type I Hyperlipoproteinemia Drug Revenue Share by Players/Suppliers

Table United States Market Type I Hyperlipoproteinemia Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)

Figure United States Market Type I Hyperlipoproteinemia Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017

Figure United States Type I Hyperlipoproteinemia Drug Market Share of Top 3 Players/Suppliers

Figure United States Type I Hyperlipoproteinemia Drug Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Type I Hyperlipoproteinemia Drug Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Type I Hyperlipoproteinemia Drug Product Category

Table United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Region (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales Share by Region

(2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Share by Region

(2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Market Share by Region in 2017

Table United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Market Share by Region (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Revenue Share by Region (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Revenue Market Share by Region (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Revenue Market Share by Region in 2017

Table United States Type I Hyperlipoproteinemia Drug Price (USD/Pcs) by Region (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales Share by Type (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Share by Type (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2017

Table United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Market Share by Type (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Revenue Share by Type (2013-2018)

Figure Revenue Market Share of Type I Hyperlipoproteinemia Drug by Type (2013-2018)

Figure Revenue Market Share of Type I Hyperlipoproteinemia Drug by Type in 2017

Table United States Type I Hyperlipoproteinemia Drug Price (USD/Pcs) by Types (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Growth Rate by Type (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2013-2018)

Table United States Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Market Share by

Application (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2017

Table United States Type I Hyperlipoproteinemia Drug Sales Growth Rate by Application (2013-2018)

Figure United States Type I Hyperlipoproteinemia Drug Sales Growth Rate by Application (2013-2018)

Table Aegerion Pharmaceuticals, Inc. Basic Information List

Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Growth Rate (2013-2018)

Figure Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Market Share in United States (2013-2018)

Figure Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share in United States (2013-2018)

Table Catabasis Pharmaceuticals, Inc. Basic Information List

Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Growth Rate (2013-2018)

Figure Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Market Share in United States (2013-2018)

Figure Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share in United States (2013-2018)

Table Isis Pharmaceuticals, Inc. Basic Information List

Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Growth Rate (2013-2018)

Figure Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales Market Share in United States (2013-2018)

Figure Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share in United States (2013-2018)

Table Novartis AG Basic Information List

Table Novartis AG Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Novartis AG Type I Hyperlipoproteinemia Drug Sales Growth Rate (2013-2018)

Figure Novartis AG Type I Hyperlipoproteinemia Drug Sales Market Share in United

States (2013-2018)

Figure Novartis AG Type I Hyperlipoproteinemia Drug Revenue Market Share in United States (2013-2018)

Table uniQure N.V. Basic Information List

Table uniQure N.V. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure uniQure N.V. Type I Hyperlipoproteinemia Drug Sales Growth Rate (2013-2018)

Figure uniQure N.V. Type I Hyperlipoproteinemia Drug Sales Market Share in United States (2013-2018)

Figure uniQure N.V. Type I Hyperlipoproteinemia Drug Revenue Market Share in United States (2013-2018)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Type I Hyperlipoproteinemia Drug

Figure Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug

Figure Type I Hyperlipoproteinemia Drug Industrial Chain Analysis

Table Raw Materials Sources of Type I Hyperlipoproteinemia Drug Major Players/Suppliers in 2017

Table Major Buyers of Type I Hyperlipoproteinemia Drug

Table Distributors/Traders List

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Price (USD/Pcs) Trend Forecast (2018-2025)

Table United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Type in 2025

Table United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Application in 2025

Table United States Type I Hyperlipoproteinemia Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)

Table United States Type I Hyperlipoproteinemia Drug Sales Volume Share Forecast by Region (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume Share Forecast by Region (2018-2025)

Figure United States Type I Hyperlipoproteinemia Drug Sales Volume Share Forecast by Region in 2025

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: United States Type I Hyperlipoproteinemia Drug Market Report 2018

Product link: <https://marketpublishers.com/r/U9AE14C1E4FEN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U9AE14C1E4FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970